Results 191 to 197 of about 178,847 (197)

Functional Suitability Evaluation of Radioimmunoconjugates of Nanobodies against PD-L1 and HER2/neu for Tumor Theranostics. [PDF]

Sovrem Tekhnologii Med
Avrov KO, Shatik SV, Shashkova OA, Pinevich AA, Terekhina LA, Gryazeva IV, Zaitsev VV, Berlina MA, Stanzhevsky AA, Samoylovich MP.   +9 more
europepmc   +1 more source

Bridging B-cell autoimmunity and oncology: the PD-1/PD-L1 paradox in systemic lupus erythematosus. [PDF]

Front Immunol
Guan Y, Chen C, Hou Y.
europepmc   +1 more source

High expression of STAT3 and PD-L1 predicts poor prognosis for laryngeal squamous cell carcinoma. [PDF]

Sci Rep
Shui T, Pan Y, Hong J.
europepmc   +1 more source

Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass Opacities. [PDF]

Cancer Med
Tang WF, Huang SQ, Lin YD, Li HJ, Huang QH, Chen J, Qiu ZB, Huang WZ, Wu YM, Ye HY, Xu W, Yang XN, Wu YL, Jiang HM, Liang Y, Tang X, Zhong WZ.   +16 more
europepmc   +1 more source

Interest of PD-L1 in the management of triple negative breast cancers in Ivorian patients. [PDF]

BMC Womens Health
Diallo A, Aman NA, Traore B, Coulibaly ZI, Kouacou BFA, Nzi MR, Doukoure B, Diomande MI.   +7 more
europepmc   +1 more source